- Home
- WSBF vs ELDN Comparison
WSBF vs ELDN Comparison
Compare WSBF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSBF | ELDN |
|---|---|---|
| Founded | 1921 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.9M | 291.8M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WSBF | ELDN |
|---|---|---|
| Price | $20.17 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 88.3K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ 46.53 | 30.67 |
| EPS | ★ 0.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.08 | $1.35 |
| 52 Week High | $21.03 | $4.60 |
Technical Indicators
Market Signals| Indicator | WSBF | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 58.76 | 40.67 |
| Support Level | $17.78 | $3.35 |
| Resistance Level | $21.03 | $4.15 |
| Average True Range (ATR) | 0.51 | 0.24 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 90.37 | 0.00 |
Price Performance
Historical ComparisonAbout WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The majority of its revenue comes from the Community Banking segment.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.